Sort
23,748 grants matching “melanoma”
Role of CD44 in EC injury and melanoma therapy
$300,000Virginia Commonwealth University · R01 · FY2003 · AI
Validation and humanization of a PET imaging agent that targets PD-L1.
$300,000Monica Gostissa · Agenus, Inc. · R43 · FY2016 · CA
Continuous exosome and oncosome separations using a modified SPLITT system
$300,000Kevin Petersen · Espira, Inc. · N01 · FY2016 · CA
Novel carcinoma-specific monoclonal antibodies for therapies and diagnostics
$300,000J. Suzanne Suzanne Lindsey · Recodagen, Llc · R43 · FY2019 · CA
VISTA: A Novel Therapeutic Target That Negatively Regulates Immunity
$300,000Susan Dana Jones · Immurx Llc · R43 · FY2011 · AI
Novel Therapeutic Vaccines for Chronic HBV
$300,000Robert Gerald Whalen · Altravax, Inc. · R43 · FY2012 · AI
Fiberoptic Microneedle Device for Combined Light and Nanomedicine Delivery: Mimicking Nature's Design of a Mosquito
$300,000Christopher G Rylander · Virginia Polytechnic Institute And State University · · FY2009 · ENG
Abramson Cancer Center Support Grant
$299,999Robert H Vonderheide · University Of Pennsylvania · P30 · FY2020 · CA
Topic 396 - Imaging for Cancer Immunotherapies-Moonshot
$299,999Arfaan Rampersaud · Columbus Nanoworks, Inc. · N43 · FY2019 · CA
Development of GPER agonists as Cancer Therapeutics
$299,998Todd W Ridky · Linnaeus Therapeutics, Llc · R41 · FY2018 · CA
Humanized Anti-Renalase Antibodies for Unresectable Melanoma
$299,996Barry A Berkowitz · Bessor Pharma, Llc · R43 · FY2018 · CA
Optimization of a novel cancer immunotherapeutic antibody for human use
$299,994Jennifer D Wu · Cancure, Llc · R41 · FY2016 · CA
Improving availability of ImmunoPET via automation of radio-synthesis and quality control of antibody-based cancer imaging PET tracers on a single platform.
$299,987Arkadij Elizarov · Trace-Ability, Inc. · R43 · FY2019 · CA
Transduction of Hematopoietic Stem Cells for Enhanced Immunotherapy of Melanoma
$299,973Donald B Kohn · California Institute Of Technology · P01 · FY2014 · CA
Overcoming anti-PD-1 resistance by systemic delivery of an oncolytic adenovirus that targets TGF-beta
$299,956Prem Seth · Multivir, Inc. · R41 · FY2018 · CA
Immunization Against Melanoma Differentiation Antigens
$299,950Jedd D. Wolchok · Sloan-Kettering Inst Can Research · R01 · FY2018 · CA
Immunization Against Melanoma Differentiation Antigens
$299,950Jedd D. Wolchok · Sloan-Kettering Inst Can Research · R01 · FY2017 · CA
Immunization Against Melanoma Differentiation Antigens
$299,950Jedd D. Wolchok · Sloan-Kettering Inst Can Research · R01 · FY2016 · CA
Development of a T cell-targeted TGF-b antagonist that reverses immune suppression in melanoma patients
$299,946Dori A Thomas-Karyat · Synthis Therapeutics, Inc. · R43 · FY2018 · CA
Chimeric Ligands for Induced Proximity (CLIP) platform for targeted proteome editing and upregulation of antigen presentation
$299,921Luiz Miguel Quinn Camargo · Ubiquitx, Inc. · R41 · FY2024 · AI
A high-throughput platform for neo-antigen based cancer immunotherapy
$299,917Jun Xiao · Immudx, Llc · R43 · FY2018 · CA
Regulation of apoptosis in melanocytic cells
$299,907Douglas Grossman · University Of Utah · R01 · FY2006 · AR
Non-catalytic FAK inhibitors as novel therapeutics for lung fibrosis
$299,905Timothy A Marlowe · Faknostics, Llc · R41 · FY2022 · HL
Cellular Redox Control and Oxidant Signaling
$299,900Duke University · R01 · FY2004 · HL
Defining a Role for c-KIT in Melanoma
$299,900Matthew Wayne Vanbrocklin · University Of Utah · R01 · FY2014 · CA